Compare DKL & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKL | XENE |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2012 | 2014 |
| Metric | DKL | XENE |
|---|---|---|
| Price | $52.49 | $54.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $51.33 | ★ $67.17 |
| AVG Volume (30 Days) | 57.1K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $2.04 | N/A |
| Revenue Next Year | $7.16 | $2,436.26 |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.59 | $26.74 |
| 52 Week High | $55.89 | $62.91 |
| Indicator | DKL | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 58.97 |
| Support Level | $50.17 | $39.93 |
| Resistance Level | $55.40 | $62.91 |
| Average True Range (ATR) | 1.57 | 2.05 |
| MACD | -0.10 | -0.33 |
| Stochastic Oscillator | 35.75 | 20.46 |
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.